CLLD6 Activators
CLLD6 activators encompass a variety of chemical compounds that engage in diverse cellular signaling pathways, each contributing to the enhancement of CLLD6 function. Forskolin, by stimulating adenylate cyclase, leads to an increase in cAMP levels, which triggers PKA activation. PKA, a pivotal kinase within cellular signaling, can phosphorylate a broad spectrum of substrates. These substrates can directly interact with or regulate the activity of CLLD6. Similarly, inhibitors of phosphodiesterases such as IBMX and Rolipram prevent the breakdown of cAMP, maintaining PKA activation and, consequently, promoting the phosphorylation state and functional activity of CLLD6.
In the context of second messenger signaling, compounds like the Epac activator 8-pCPT-2'-O-Me-cAMP and G-protein-coupled receptor ligands such as LPA and S1P orchestrate downstream signaling events that culminate in theactivation of CLLD6. 8-pCPT-2'-O-Me-cAMP activates Epac, leading to the activation of Rap1, a small GTPase that modulates various signaling pathways involved in the regulation of CLLD6. LPA and S1P, through their respective GPCR-mediated pathways, activate Rho GTPases that are central to cytoskeletal rearrangements and cellular signaling modifications, subsequently influencing the activity of CLLD6. Additionally, the PI3K activator 740 Y-P enhances the PI3K/Akt signaling pathway, which is involved in a multitude of cellular processes, including those that could intersect with the regulatory mechanisms of CLLD6. Akt, a serine/threonine-specific protein kinase, can phosphorylate a range of substrates that in turn may regulate CLLD6 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, which increases intracellular cAMP levels. This rise in cAMP activates PKA. PKA can phosphorylate specific substrates that are involved in the regulation of CLLD6, thus enhancing its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP and cGMP. By preventing cAMP degradation, IBMX can indirectly increase the activity of PKA, which may then enhance the phosphorylation state and activity of CLLD6. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a selective PDE4 inhibitor, increases cAMP levels specifically in cells where PDE4 is the predominant cAMP-degrading enzyme. The resulting activation of PKA can enhance the phosphorylation and function of CLLD6. | ||||||
8-pCPT-2′-O-Me-cAMP | 634207-53-7 | sc-257020 | 1 mg | $306.00 | 5 | |
8-pCPT-2'-O-Me-cAMP selectively activates Epac, a guanine nucleotide exchange factor directly activated by cAMP, which in turn activates Rap1. Rap1 can influence downstream effectors that modulate CLLD6 activity. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
Lysophosphatidic acid (LPA) activates G-protein-coupled receptors, which can lead to the activation of Rho GTPases. Rho GTPases can modulate actin dynamics, potentially influencing CLLD6 activity due to its association with cytoskeletal elements. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its receptors leading to downstream activation of Rho GTPases, which can then influence the cytoskeletal organization and cellular signaling pathways that enhance CLLD6 activity. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is a potent inhibitor of protein phosphatases 1 and 2A. Inhibition of these phosphatases can lead to increased phosphorylation levels of proteins, which may include substrates that affect CLLD6 function, thereby enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is an activator of protein kinase C (PKC). PKC phosphorylates a wide range of cellular proteins, which can include those that regulate or modify the activity of CLLD6. | ||||||
Bradykinin | 58-82-2 | sc-507311 | 5 mg | $110.00 | ||
Bradykinin binds to B2 receptors and activates PLC, which catalyzes the production of IP3 and DAG, leading to the release of calcium and activation of PKC. This cascade can lead to changes in the cellular environment that enhance CLLD6 activity. | ||||||
SKL2001 | 909089-13-0 | sc-507410 | 10 mg | $123.00 | ||
SKL2001 activates the Wnt/β-catenin signaling pathway, which can upregulate the expression of genes and the activity of proteins involved in the same cellular processes as CLLD6, thereby enhancing its activity. | ||||||